Compare GSUN & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSUN | NRXS |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 25.8M |
| IPO Year | 2022 | 2023 |
| Metric | GSUN | NRXS |
|---|---|---|
| Price | $1.56 | $2.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 212.4K | 62.2K |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,314,724.00 | $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 526.22 | 36.89 |
| 52 Week Low | $1.25 | $1.33 |
| 52 Week High | $5.25 | $6.20 |
| Indicator | GSUN | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 48.63 |
| Support Level | $1.29 | $2.65 |
| Resistance Level | $1.58 | $2.82 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 72.09 | 74.21 |
Golden Sun Health Technology Group Ltd is a holding company. Along with its subsidiaries, it is engaged in the provision of education services and e-commerce business in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistics and consulting services. It has also established its wellness brands and an e-commerce platform to promote and sell wellness products. The company operates in the following segments; Education, which generates maximum revenue, and E-commerce.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).